Danish biotechnology company Genmab has partnered with US-based technology firm Tempus to research and develop disease targets in oncology.

Tempus uses artificial intelligence to advance precision medicine.

As part of the multi-year alliance, Tempus will combine its sequencing capabilities, as well as its clinical and molecular data platform with Genmab’s expertise in target, biomarker and translational discovery.

The partners will leverage Genmab insights to advance targets and biomarkers that have the potential to develop new treatments for cancer.

Under the partnership, the companies will work together on research projects identified by Genmab, which will be responsible for the development and commercialisation of any resulting products.

In turn, Tempus will receive milestone payments and royalties. The company will also have the option to partially fund development programmes for increased royalty payments.

Genmab CEO Jan van de Winkel said: “Tempus has built the world’s largest library of clinical and molecular data, is a leader in the field of personalised medicine and like Genmab, Tempus has a mission to improve the lives of cancer patients.

“We are looking forward to expanding our exciting partnership with them and to the possibility of discovering important new oncology targets and biomarkers.”

Genmab was founded in 1999 and focuses on antibody therapeutics to treat patients with cancer.

Its portfolio includes Darzalex (daratumumab), for treating some multiple myeloma indications and Arzerra (ofatumumab) for select chronic lymphocytic leukaemia patients. Genmab is also developing several other clinical and pre-clinical products.

The company’s antibody technologies include DuoBody, to create bispecific antibodies, as well as HexaBody to produce effector function enhanced antibodies.

Furthermore, it also has the HexElect platform, comprising a combination of two co-dependently acting HexaBody molecules for selectivity and maximum therapeutic potency, as well as the DuoHexaBody platform to improve the potency of bispecific antibodies.